NADPH oxidase-IN-1

• UNSPSC Description:

  NADPH oxidase-IN-1 is an orally active NADPH oxidase (Nox) inhibitor, related with neuronal inflammation. NADPH oxidase-IN-1 can cross the blood-brain barrier (BBB), inhibits Nox2 and Nox4 with IC50s of 1.9 μM and 2.47 μM, respectively. NADPH oxidase-IN-1 suppresses pro-inflammatory cytokines production and LPS-mediated microglial migration, also has in vivo efficacy[1].

• Target Antigen:

  NADPH Oxidase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/nadph-oxidase-in-1.html

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CN(C1=CC=C(C=C1)/C=C2C(N(C(N\2C)=S)C3CCCCC3)=O)CCO

• Molecular Weight:

  373.51

• References & Citations:

  [1]Shim S, et al. Discovery of a NADPH oxidase inhibitor,(E)-3-cyclohexyl-5-(4-((2-hydroxyethyl)(methyl) amino) benzylidene)-1-methyl-2-thioxoimidazolidin-4-oneone, as a novel therapeutic for Parkinson's disease[J]. European Journal of Medicinal Chemistry, 2022, 244: 114854.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2762405-17-2